Saudi Arabia has made significant strides in the biotechnology sector following the launch of its national strategy in early 2024, aiming to position itself as a leading global hub in the field.
The Kingdom has witnessed rapid developments in regulatory frameworks and infrastructure, facilitating the establishment of research centers and specialized laboratories that drive progress toward the strategy’s goals.
Biotechnology is a broad scientific and technological discipline involving the use of microorganisms, cells, and biological systems to develop products and applications that benefit various industries. It is considered a key tool for fostering development and enhancing societal well-being.
Prince Mohammed bin Salman, Crown Prince and Prime Minister, launched the National Biotechnology Strategy in January last year, aiming to make the sector contribute 3% to the Kingdom’s non-oil GDP by 2040, with a total economic impact of 130 billion riyals ($35 billion).
The strategy is expected to drive the expansion of the biotechnology industry while creating high-quality jobs in the coming years, with more than 11,000 positions projected by 2030.
The global biotechnology market was valued at around $1.5 trillion in 2023 and is projected to reach $4 trillion by 2030, according to a report by consultancy firm Arthur D. Little last year.
The forecast underscores the sector’s rapid growth, positioning biotechnology not only as a driver of scientific advancement but also as a major economic opportunity.
Saudi Arabia has established specialized research centers and advanced laboratories while localizing key industries such as insulin and vaccine production. At the same time, the Kingdom has strengthened collaboration with global institutions, accelerating innovation and enhancing self-sufficiency.
Saudi Bio, the Kingdom’s first biotechnology firm focused on technology transfer and localizing biotech industries, has made significant strides in this effort.
Dr. Khaled Al-Mosa, the company’s founder and vice chairman, highlighted the Kingdom’s progress, emphasizing that Saudi Arabia’s transformation is not limited to infrastructure development but also includes building a supportive regulatory environment that has made it an attractive destination for biotech companies.
“Saudi Arabia has undergone a major shift since launching its biotechnology strategy,” Al-Mosa told Asharq Al-Awsat.
“The Kingdom has achieved several milestones, including establishing specialized research centers, advanced laboratories, and leading national companies in the biotech field,” he remarked.
Collaboration with leading global research and development institutions has been a key driver of Saudi Arabia’s progress in biotechnology, helping to develop new technologies and scientific breakthroughs, according to Al-Mosa.
He noted that the Kingdom has successfully localized several critical industries, including insulin and vaccine production, boosting self-sufficiency and reducing reliance on imports.
Saudi Arabia’s supportive regulatory framework has also facilitated the growth of biotech firms, Al-Mosa said. The national strategy has streamlined licensing procedures and introduced financial and customs incentives to attract local and foreign investment.
The Kingdom has further strengthened its research and training capabilities by establishing specialized training centers and offering research grants for scientists, accelerating innovation and production. These initiatives, he added, have positioned Saudi Arabia as a preferred destination for biotechnology companies.
Looking ahead, Al-Mosa expressed optimism about the sector’s growth, driven by continued investment in research, development, and training. He expects an increase in biotech startups and new projects, enhancing Saudi Arabia’s global competitiveness.
